Wall Street brokerages expect that Definitive Healthcare Corp. (NASDAQ:DH – Get Rating) will report $53.59 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Definitive Healthcare’s earnings, with the highest sales estimate coming in at $54.00 million and the lowest estimate coming in at $52.95 million. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Definitive Healthcare will report full-year sales of $222.84 million for the current year, with estimates ranging from $220.03 million to $224.30 million. For the next fiscal year, analysts anticipate that the company will post sales of $282.52 million, with estimates ranging from $275.89 million to $289.48 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Definitive Healthcare.
Definitive Healthcare (NASDAQ:DH – Get Rating) last issued its earnings results on Wednesday, February 23rd. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.02. The company had revenue of $46.31 million for the quarter, compared to analyst estimates of $44.78 million.
A number of research firms recently weighed in on DH. Canaccord Genuity Group raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating and lowered their price target for the company from $46.00 to $28.00 in a report on Thursday, February 24th. Credit Suisse Group cut their price objective on shares of Definitive Healthcare from $30.00 to $24.00 and set a “neutral” rating on the stock in a research report on Thursday, February 24th. Canaccord Genuity Group upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Thursday, February 24th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Definitive Healthcare from $21.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, April 5th. Finally, Zacks Investment Research downgraded shares of Definitive Healthcare from a “hold” rating to a “sell” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Definitive Healthcare currently has a consensus rating of “Hold” and a consensus target price of $37.00.
In other news, CFO Richard Douglas Booth purchased 2,374 shares of the business’s stock in a transaction on Thursday, March 3rd. The shares were acquired at an average cost of $21.06 per share, with a total value of $49,996.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Charles Haywood sold 18,315 shares of the business’s stock in a transaction on Wednesday, May 11th. The shares were sold at an average price of $15.46, for a total transaction of $283,149.90. The disclosure for this sale can be found here. Corporate insiders own 17.52% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of DH. Echo Street Capital Management LLC raised its position in shares of Definitive Healthcare by 174.3% in the first quarter. Echo Street Capital Management LLC now owns 5,512,182 shares of the company’s stock worth $135,875,000 after acquiring an additional 3,502,444 shares during the period. Conestoga Capital Advisors LLC grew its stake in Definitive Healthcare by 80.3% during the 1st quarter. Conestoga Capital Advisors LLC now owns 3,533,860 shares of the company’s stock valued at $87,110,000 after acquiring an additional 1,574,237 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Definitive Healthcare by 59.4% during the 1st quarter. JPMorgan Chase & Co. now owns 2,552,265 shares of the company’s stock valued at $62,914,000 after acquiring an additional 951,576 shares in the last quarter. BlackRock Inc. grew its stake in shares of Definitive Healthcare by 50.4% in the 4th quarter. BlackRock Inc. now owns 2,256,587 shares of the company’s stock valued at $61,672,000 after buying an additional 756,587 shares during the period. Finally, Clearbridge Investments LLC grew its stake in shares of Definitive Healthcare by 17.8% in the 1st quarter. Clearbridge Investments LLC now owns 2,077,794 shares of the company’s stock valued at $51,218,000 after buying an additional 314,089 shares during the period. Institutional investors own 99.42% of the company’s stock.
NASDAQ:DH opened at $16.47 on Friday. The firm’s 50 day moving average is $22.68 and its two-hundred day moving average is $25.22. Definitive Healthcare has a fifty-two week low of $14.76 and a fifty-two week high of $50.30. The company has a quick ratio of 3.21, a current ratio of 3.21 and a debt-to-equity ratio of 0.18.
Definitive Healthcare Company Profile (Get Rating)
Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution.
Get a free copy of the Zacks research report on Definitive Healthcare (DH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Definitive Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Definitive Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.